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and Lennart Jacobsson1
Abstract
Background: The effect of circumstances and exposures early in life on the risk of developing ankylosing
spondylitis (AS) is largely unknown. The purpose of this study was to determine whether perinatal characteristics
predict development of AS.
Methods: AS cases (n = 1960; 59 % men) were defined as listed with a diagnosis of AS at least once in the Swedish
National Patient Register and registered in the Swedish Medical Birth Register (born ≥1973). Population controls
were retrieved from the Swedish Population Register (n = 8378; mean 4.3 controls/case), matched on birth year, sex
and county. Odds ratios (OR) for developing AS were determined through conditional logistic regression, with
regard to: birth weight, birth order, season of birth, maternal age, gestational length, size for gestational age, type
of birth, mode of delivery, congenital malformations, mothers’ country of birth, mothers’ civil status and size of
delivery unit.
Results: In the univariate analyses statistically significant increases in risk for developing AS were observed for
having older siblings (OR 1.18; 95 % Cl 1.06–1.30). No association was observed for the remainder of analysed
exposures, although there was a weak association with birth weight below 3000 g (OR 1.19; 95 % CI 1.04–1.37),
though not for “low birth weight” <2500 g (OR 0.90; 95 % CI 0.70–1.16). The increase in risk associated with having
older siblings was consistent in a multivariate analysis adjusting for possible confounders (OR 1.23; 95 % Cl 1.09–1.39).
The direction and magnitude of the point estimates were also consistent in several sensitivity analyses and when
stratifying by sex.
Conclusions: Having older siblings was associated with an increased risk for developing AS. These results need to be
repeated and confirmed in other cohorts.
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Background
Ankylosing spondylitis (AS) is a chronic and progressive
inflammatory disease with onset of symptoms before the
age of 45 in the majority of cases, and an estimated
1.30–1.56 million prevalent cases in Europe [1, 2]. Other
common inflammatory diseases, such as inflammatory
bowel disease (IBD), psoriasis, and anterior uveitis are
overrepresented in AS, suggesting shared aetiology [3].
The strong correlation between AS and the human
leukocyte antigen (HLA) B27 has been extensively inves-
tigated [4–8]. Based on twin studies the majority of the
susceptibility for AS can be attributed to genetic factors
[3], but environmental factors are also likely to contrib-
ute to the risk [9, 10], a contribution that may differ
depending on phenotype, sex, or age of onset. One pro-
posed hypothesis states that infections may trigger the
disease onset in genetically susceptible individuals [10],
in similarity to the related disease reactive arthritis [11,
12]. Another hypothesis suggests that mechanical stress
* Correspondence: ulf.lindstrom@gu.se
1Department of Rheumatology and Inflammation Research, Institute of
Medicine, Sahlgrenska Academy, University of Gothenburg, Guldhedsgatan
10A, 405 30 Gothenburg, Sweden
Full list of author information is available at the end of the article
© 2016 Lindström et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Lindström et al. Arthritis Research & Therapy  (2016) 18:16 
DOI 10.1186/s13075-016-0917-1
at the entheses may initiate inflammation and bone re-
modelling [13]. However, so far the evidence supporting
the role of specific environmental risk factors in the de-
velopment of AS has been limited.
Number of siblings is often applied as a proxy for ex-
posure to childhood infections and has been shown to
affect the risk for developing immune-related diseases
[14]. Studies have found an inverse relationship between
sibship size and risk for allergic diseases, such as child-
hood asthma and eczema [15–17]. This has been attrib-
uted to the “hygiene hypothesis”, postulating that an
increased exposure to infections during childhood may
lead to a lower risk for developing allergy [18]. Two
previous studies, investigating the effect of birth order
on the risk for developing AS have produced conflicting
results [19, 20].
The relationship between exposures even earlier in life,
such as factors influencing pregnancy and birth, and
later development of disease has been established for
diabetes and cardiovascular disease but it has also been
implicated in several diseases characterised primarily by
inflammation or autoimmunity [21]. Low birth weight
has, for example, been associated with a decreased risk
for later development of rheumatoid arthritis (RA), and
high birth weight with an increased risk [22–24]. High
birth weight may also be associated with an increased
risk of Sjögren’s syndrome [25]. Similarly, season of birth
has also been shown to be associated with variations in
the risk for subsequent development of certain diseases.
For example, children born during autumn and winter
months have been shown to have a higher risk for food
allergy (suggested to be related to UVB exposure and
vitamin D) [26, 27]. Other studies have also indicated a
variation in the risk for development of IBD, depending
on season or month of birth [28, 29].
No large population-controlled studies have been per-
formed investigating how circumstances and exposures
early in life affect the risk of developing AS. The over-
arching aim of this study was to assess the role of envir-
onmental factors, specifically pregnancy and perinatal
characteristics, in the pathogenesis of AS, with particular
focus on birth order, birth weight and season of birth.
Methods
Setting and data sources
This is a case–control study, based on the Swedish na-
tional health care and population registers.
The Swedish National Patient Register (NPR) was ini-
tiated in 1964, as an inpatient register collecting admin-
istrative and medical data, including diagnoses registered
according to the Swedish version of the International
Classification of Diseases (ICD) [30] codes at discharge
from hospital. Since 1987 the coverage is considered to
be close to 100 % [31]. In 2001 an outpatient register
was added for outpatient specialized care. The coverage
is lower, approximately 80 %, mostly due to missing data
from private care [32]. The NPR is considered to have a
very high validity in general [33]. Primary care visits are
not included in the NPR.
The Swedish population register, managed by Statistics
Sweden, contains data on residence, migration and
socioeconomic factors for all residents [34].
The Swedish Medical Birth Register (MBR) was initi-
ated in 1973 and includes administrative and medical
data related to pregnancy, partum and postpartum
neonatal care [35]. It is compulsory for all health care
providers involved in prenatal maternity care, delivery
or neonatal care to report to the register.
The Prescribed Drug Register contains data on all
drugs prescribed in Sweden since July 2005, e.g. date
prescribed/dispensed, dose and Anatomical Therapeutic
Chemical code (ATC code [36]). The Anti-Rheumatic
Therapy in Sweden (ARTIS) Register is a national treat-
ment register, aimed at monitoring disease activity and
outcome and safety of pharmacological treatment (in-
cluding biological drugs) in rheumatic diseases. All pub-
lic and private rheumatology clinics report to the
register, which has an estimated national coverage of
85–95 % for patients treated with tumour necrosis factor
inhibitors (TNFi) [37, 38].
All the registers include the individuals personal iden-
tification number (PIN), given to all residents in Sweden,
enabling cross-linking of different registers [39].
In this study the NPR was used to identify the AS
cases and to retrieve data on AS-related inflammatory
diseases 1973–2009. Matched controls (see below) were
obtained from the population register and data on peri-
natal characteristics from the MBR. Data on pharmaco-
logical treatment were retrieved from the Prescribed
Drug Register and the ARTIS register. All ICD and ATC
codes used are presented in supplementary Table S1
(Additional file 1).
Study population
AS cases were defined as all individuals registered in the
MBR (born in Sweden ≥1973) who at least once up until
2009 had a visit listing an ICD code for AS (ICD-8: 712,
40, ICD-9: 720A, ICD-10: M45) registered in the NPR.
We have previously performed a validation study of the
AS diagnoses in the NPR and found good validity, with a
positive predictive value of at least 80 % for fulfilling the
modified New York criteria and 89–97 % fulfilling any of
the commonly used classification criteria for spondyloar-
thritis (SpA) [40].
For each AS case five controls, matched on birth year,
sex and county of residence (at the time of their first
SpA diagnosis), were retrieved from the population
register. Matching at the time of the first SpA diagnosis,
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rather than the first AS diagnosis, was chosen as the
preferred method of matching since a number of cases
were expected to first receive another SpA diagnosis be-
fore development and subsequent documentation of
structural changes of the sacroiliac joints or spine,
resulting in a diagnosis of AS. From the population
register we also retrieved data on level of formal edu-
cation and disposable income in 2008, which was
used to compare socioeconomic status between cases
and controls.
Data on AS-related disease manifestations, conven-
tional synthetic disease-modifying anti-rheumatic drugs
(csDMARDs) and TNFi were used for a stratification of
disease severity for the AS cases in the sensitivity ana-
lyses: from the NPR we collected data on all registered
visits to a non-primary care physician with an ICD code
attributed to some of the AS-related inflammatory dis-
eases (IBD, psoriasis, and anterior uveitis) for both cases
and controls, from birth and up to 2 years after the first
AS diagnosis for the index case (at the latest up until 31
December 2011). A 2-year lag period after the first diag-
nosis of AS was chosen to include patients diagnosed
with IBD and psoriasis as a result of medical investiga-
tions initiated at the time of the first AS diagnosis.
For the AS cases data on pharmacological treatment,
prescribed between 1 January 2011 and 31 December
2011, were obtained from the Prescribed Drug Register
for the following csDMARDS: methotrexate and
sulphasalazine; and for subcutaneously administered
TNFi: etanercept, adalimumab, golimumab and certoli-
zumab pegol. From the ARTIS we obtained data on reg-
istered treatment with infliximab for the same time
period, since this intravenously administered TNFi is
normally not prescribed through a pharmacy and thus
not included in the Prescribed Drug Register.
Exposure data
Variables associated with birth characteristics were re-
trieved from the MBR. The variables assessed were: ma-
ternal age, mother’s country of birth (Sweden, Nordic or
other), mother’s civil status (mother married or living
with father of the child versus other situation, as re-
corded in the MBR), number of older siblings, season of
birth, mode of delivery (caesarean/vaginal), type of birth
(single/multiple), birth weight, birth length, gestational
length, birth weight for gestational age [41], congenital
malformations, and maternal smoking during pregnancy.
In order to adjust for systematic errors arising from pos-
sible variations in practice between delivery units, a vari-
able coding for size of delivery unit (based on number of
deliveries in the MBR during the study period) was also
included. The categories used in the analyses are pre-
sented in Table 2. Birth weight was defined as low birth
weight <2500 g, normal birth weight 2500–4200 g and
high birth weight ≥4300 g. Additional definitions, using
alternative cutoffs, were also analysed: <3310 g, 3310–
3725 g and ≥3726 g (tertiles) as well as <3000 g, 3000–
3999 g and ≥4000 g (to enable comparisons with previ-
ous similar studies [24]). Data on a recorded diagnosis of
diabetes, among the mothers prior or during the preg-
nancy, were also obtained from the MBR.
Statistics
Univariate odds ratios (ORs) were computed for the as-
sociation between exposures (birth characteristics) and
the outcome (a diagnosis of AS), by use of conditional
logistic regression.
Birth weight and birth order were also assessed in a
multivariate conditional logistic regression analysis,
which also included possible confounders (gestational
length, maternal age and type of birth (single/multiple)).
Two measures of socioeconomic status (mother’s coun-
try of birth and civil status) as well as size of the delivery
unit were also included. Season of birth was not entered
in the multivariate analysis as the univariate analysis did
not reveal any sign of association to development of AS.
The univariate and the main multivariate analyses
were also stratified by sex and by birth year above or
below the median.
Four sensitivity analyses, essentially subset analyses,
were performed, using the same multivariate model as
described above. First, excluding all cases and controls
with a diagnosis of psoriasis, anterior uveitis, or IBD be-
fore or within 2 years after the first AS diagnosis of the
index case (excluding 26 % of the entire study popula-
tion). Second, restricting the analyses to only include
cases treated with methotrexate, sulphasalazine, or TNFi
during the last year of data collection (2011), limiting
the analyses to a presumably more severe subgroup of
AS (excluding 64 % of the entire study population).
Third, limiting the analysis only to the cases who had re-
ceived their AS diagnosis at least once from a specialist
in rheumatology or internal medicine (excluding 27 % of
the entire study population). Fourth, limiting the analysis
only to cases who had received an AS diagnosis at least
once in outpatient specialized care 2001–2009 (exclud-
ing 7 % of the entire study population). An additional
analysis, based on only cases and controls still living in
their county of birth at the time point of matching, was
also performed to minimize the possible influence of mi-
gration between regions with different prevalences of an-
kylosing spondylitis.
Level of formal education and disposable income in
2008 were compared between cases and controls. Level
of formal education was categorized as ≤9, 10–12 and
>12 years of schooling and compared using a chi-square
test. Disposable income in 2008 was only assessed for
those ≥30 years old in 2008, an age when most
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individuals are assumed to have finalized their formal
education, and in order to avoid extreme outliers we
only included the 0.5th to the 99.5th percentile. Compari-
son of disposable income was performed using the t test.
Comparisons of the proportion of mothers with diabetes,
between cases and controls, were performed based on
Fisher’s exact test.
SAS version 9.3 for Windows (SAS Institute, Cary,
NC, USA) was used for aggregation of the data, and
SPSS version 21 for Windows (IBM Corp., Armonk, NY,
USA) was used for the statistical analyses.
Ethical approval
The study was approved by the regional ethics commit-
tee in Stockholm, Sweden, 9 September 2011 (number:
2011/29-31/1) and conducted in compliance with the
Declaration of Helsinki. Informed consent from individ-
ual patients/controls was not required.
Results
Cases and controls
We identified 1960 AS cases (59 % men) and 8377
matched population controls, included in the MBR
(born in Sweden after 1972). A total of 95 % of the cases
had ≥3 matched controls. Median age at inclusion
(matched at first SpA diagnosis) was 25 years (25th-
percentile = 20; 75th percentile = 28). Demographics,
pharmacological treatment, AS-related inflammatory dis-
eases and level of formal education and disposable income
in 2008 are presented in Table 1. No statistically signifi-
cant difference was observed between cases and controls
with respect to level of formal education, disposable in-
come or maternal diabetes prior or during pregnancy.
Univariate analyses
In the univariate analyses a statistically significant asso-
ciation with AS (Table 2) was observed for having older
siblings (OR 1.18; 95 % confidence interval (CI) 1.06–
1.30). There was no association between season of birth,
or birth weight defined as <2500/2500–4200/≥4200
grams, and risk of AS. Categorizing birth weight accord-
ing to previous similar studies [24] resulted in a weak
but significant association for a birth weight <3000 g
(OR 1.19; 95 % CI 1.04–1.37; 3000–4000 g: reference;
>4000 g: OR 1.04; 95 % CI 0.91–1.19) and categorizing
into tertiles resulted in similar, but non-significant point
estimates (<3310 g: OR 1.11; 95 % CI 0.99–1.25; 3310–
3725 g: reference; >3725 g: OR 1.03 95 % CI 0.91–1.65).
For the remainder of the analysed variables there were
no statistically significant associations with the outcome
of developing AS, although the point estimate for mul-
tiple births (OR 1.35; 95 % CI 0.95–1.90) indicated an
association, but based on very few events (men = 27
(2.3 %), women = 17 (2.1 %)). Further analysis of multiple
births revealed that it was associated with development
of AS only for men (OR 1.80; 95 % CI 1.14–2.84) and
not for women (OR 0.95; 95 % CI 0.55–1.63). Due to
lack of a unique identifier for the mothers, our data did
not permit us to identify cases or controls belonging to
the same multiple birth (e.g. twins), but eight possible
Table 1 Characteristics of the 1960 cases with ankylosing
spondylitis and the 8377 matched population controls
Demographics Cases
n = 1960
Controls
n = 8377
Women (%) 801 (41) 346 (41)
Year of birth median (Q1,Q3) 1979 (1975, 1984) 1979 (1975, 1984)
Age at first AS diagnosis median
(Q1, Q3)
27 (22, 30) NA
Living in same county at time
of matching and at birth
1299 (66) 5571 (67)
AS-related inflammatory diseasesa
Anterior uveitis (%) 337 (17) 22 (0)
Inflammatory bowel disease (%) 108 (6) 58 (1)
Psoriasis (%) 89 (5) 49 (1)
Any of the manifestations
above (%)
496 (25) 127 (2)
Rheumatic diagnoses before first AS diagnosisb
Spondyloarthritis diagnosisc 627 (32) NA
Any rheumatic diagnosisd 630 (32) NA
Pharmacological treatment in 2011e
TNF-alpha inhibitor (%) 494 (25) NA
Methotrexate (%) 161 (8) NA
Sulphasalazine (%) 217 (11) NA
Any of the treatments above (%) 700 (36) NA
Years of formal of education in 2008f
0–9 years 309 (16) 1160 (14)
10–12 years 880 (45) 3705 (44)
>12 years 679 (35) 2993 (36)
Disposable income in 2008 £
mean (SD)g
16378 (6797) 16768 (7050)
Maternal diabetes (%)h 12 (0.6) 36 (0.4)
AS ankylosing spondylitis. NA no data available, TNF tumour necrosis factor
aAS-related inflammatory diseases are given as cumulative incidence until
2 years after first AS diagnosis for the cases and their matched controls
bRheumatic diagnoses before first AS diagnosis are based on ICD codes in the
National Patient Register
cPsoriatic arthritis, undifferentiated spondyloarthritis, reactive arthritis and
spondyloarthritis associated with inflammatory bowel disease
dAny rheumatic disease, see Table S1 in Additional file 1
ePharmacological treatment is based on data in the Prescribed Drug Register
for prescriptions during 2011, or in the case of infliximab recoded in the
Anti-Rheumatic Therapy in Sweden (ARTIS) register as used during 2011
fNo statistically significant difference in level of formal education based on
chi-square test (p = 0.115)
gLimited to those ≥30 years old in 2008 and the 0.5th to the 99.5th percentiles
(cases = 953; controls = 3977), no statistically significant difference based on
t test (p = 0.125)
hMaternal diabetes prior or during pregnancy, as recorded in the Medical Birth
Register. No statistically significant difference based on Fisher’s exact
test (p = 0.271)
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twin pairs (born on the same day, at the same delivery
unit) were identified, with no unexpected preponderance
for either cases or controls. There was no association be-
tween maternal smoking and development of AS (OR
0.96; 95 % CI 0.78–1.17), although this was only avail-
able in cases born 1982 and later and in a total for 31 %
of the cases. No interactions were observed between ma-
ternal smoking and birth weight or having older siblings.
Multivariate analyses
The main multivariate analysis (Fig. 1) confirmed the as-
sociations observed in the univariate analyses. The ORs
for being diagnosed with AS compared to controls were
1.23 (95 % CI 1.09–1.39) for having older siblings versus
not. The ORs for birth weight were also similar in the
Table 2 Birth characteristics for ankylosing spondylitis compared
to matched population controls, with univariate odds ratios
Cases (%) Controls
(%)
OR (95 % Cl)
(n = 1960) (n = 8377)
Maternal age, years
<25 643 (33) 2676 (32) 1.04 (0.92 to 1.17)
25–29 729 (37) 3156 (38) 1 (reference)
30–34 419 (21) 1815 (22) 1.00 (0.87 to 1.14)
35+ 169 (9) 730 (9) 1.01 (0.84 to 1.21)
Missing 0 0
Mothers’ civil status
Mother married
or living with
father of the child
1322 (67) 5753 (67) 1 (reference)
Other 463 (24) 1896 (23) 1.06 (0.94 to 1.21)
Missing 175 (9) 728 (9)
Mothers’ country
of birth
Sweden 1762 (90) 7550 (90) 1 (reference)
Nordic 107 (6) 385 (5) 1.17 (0.93 to 1.47)
Other 91 (5) 442 (5) 0.81 (0.64 to 1.03)
Missing 0 0
Number of older
siblings
0 750 (38) 3550 (42) 1 (reference)
≥1 1210 (62) 4827 (58) 1.18 (1.06 to 1.30)
Missing 0 0
Type of birth
Singletons 1916 (98) 8236 (98) 1 (reference)
Multiple birth 44 (2) 141 (2) 1.35 (0.95 to 1.90)
Missing 0 0
Mode of delivery
Vaginal 1742 (89) 7544 (90) 1 (reference)
Caesarean 218 (11) 833 (10) 1.14 (0.97 to 1.33)
Missing 0 0
Season of birth
March-May 568 (29) 2354 (28) 1 (reference)
June-August 473 (24) 2073 (25) 0.95 (0.83 to 1.09)
September-November 416 (21) 1969 (24) 0.87 (0.76 to 1.00)
December-February 503 (26) 1981 (24) 1.04 (0.91 to 1.19)
Missing 0 0
Birth weight, g
<2500 76 (4) 355 (4) 0.90 (0.70 to 1.16)
2500–4200 1764 (90) 7476 (89) 1 (reference)
≥4200 113 (6) 536 (6) 0.90 (0.73 to 1.11)
Missing 7 (0) 10 (0)
Table 2 Birth characteristics for ankylosing spondylitis compared
to matched population controls, with univariate odds ratios
(Continued)
Gestational length, days
≤258 111 (6) 455 (5) 1.02 (0.82 to 1.27)
259–293 1611 (82) 6846 (82) 1 (reference)
≥294 196 (10) 915 (11) 0.92 (0.78 to 1.08)
Missing 42 (2) 161 (2)
Birth weight for
gestational agea
Small for
gestational age
66 (3) 316 (4) 0.89 (0.68 to 1.17)
Appropriate for
gestational age
1788 (91) 7652 (91) 1 (reference)
Large for
gestational age
49 (3) 227 (3) 0.95 (0.69 to 1.31)
Missing 57 (3) 183 (2)
Congenital
malformation
No 1829 (93) 7760 (93) 1 (reference)
Yes 75 (4) 354 (4) 0.90 (0.70 to 1.17)
Missing 57 (3) 182 (2)
Size of delivery unit
(no of births ≥1973)
≥300 484 (25) 2087 (25) 0.91 (0.76 to 1.09)
200–299 581 (30) 2502 (30) 0.92 (0.78 to 1.09)
100–199 598 (31) 2471 (30) 1 (reference)
<100 297 (15) 1317 (16) 0.93 (0.77 to 1.13)
Maternal smokingb
Not smoking
during pregnancy
170 (9) 769 (9) 1 (reference)
Smoking during
pregnancy
440 (22) 1896 (23) 0.96 (0.78 to 1.17)
Missing 1350 (69) 5713 (68)
Odds ratios (ORs) determined through conditional logistic regression analyses
aMultiple births excluded since reference intervals are not applicable
bOnly available from 1982, when recording of maternal smoking was initiated
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multivariate analysis, compared to the univariate. None
of the other exposures in the multivariate analysis were
significantly associated with the development of AS and
no point estimates except for multiple births (OR 1.25;
95 % CI 0.84–1.84) indicated a possible association.
Sensitivity analyses
Overall, the OR for having older siblings was similar in
all sensitivity analyses (Fig. 1), to those in the main ana-
lyses. Stratifying the univariate and multivariate analyses
by sex and median birth year resulted in overall similar
point estimates as in the stratified univariate analyses,
supplementary Table S2 (Additional file 2). Multivariate
analysis, only including cases and controls still living in
their birth county, at the time of matching, revealed no
important differences to the main analysis.
Discussion
Principal findings
In this study having older siblings was associated with
an increased risk of receiving a diagnosis of AS. There
was also a weak increase in risk associated with a birth
weight <3000 g, which could not be confirmed in our
primary stratifications of birth weight. We found no as-
sociation between, season of birth, type of birth, mode
of delivery, congenital malformations, gestational length
or maternal age, and later being diagnosed with AS.
Comparison to previous studies
Birth weight has to our knowledge not been studied as a
risk factor for being diagnosed with AS. For IBD, which
is associated with AS, one case–control study indicated
that cases developing IBD had significantly lower birth
weight compared to controls [42], which in that study
was probably related to a significantly higher frequency
of preterm birth. In our study there was no association
between neither birth weight nor gestational length and
development of AS in the univariate or any of the multi-
variate analyses, using the definition for low birth weight
set by the World Health Association [43]. However,
when using the alternative stratification of birth weight
(<3000 g, 3000–4000 g, >4000 g), there was a slight in-
crease in risk for birth weight <3000 g, and similarly so
when birth weight was categorized into tertiles. This
Fig. 1 Odds ratios for developing ankylosing spondylitis with regard to having older siblings. Forest plot presenting odds ratios with 95 % confidence
intervals for being diagnosed with ankylosing spondylitis, with regard to having older siblings, in a multivariate conditional logistic regression analysis
and four sensitivity analyses. All the analyses were adjusted for birth weight, having older siblings, mother’s birth country, mother’s civil status, maternal
age, gestational length, type of birth (single/multiple) and size of delivery unit. *All cases with an ICD code for psoriasis, anterior uveitis or inflammatory
bowel disease before or within 2 years of their AS diagnosis, and their respective controls are excluded. †Including only cases, with their respective
controls, who had received ≥1 AS diagnosis at a clinic of rheumatology or internal medicine. ††Including only cases with their respective controls who
had received ≥1 AS diagnosis in the outpatient register 2001–2011. ‡Including only cases, with respective controls who were treated with csDMARDs
(methotrexate and sulphasalazine) and/or TNFi during any part of 2011. AS ankylosing spondylitis, csDMARDs conventional synthetic disease-modifying
anti-rheumatic drugs, ICD International Classification of Diseases, TNFi tumour necrosis factor inhibitor
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suggests differences in the distribution of birth weight
between those later developing AS compared to con-
trols, although the biological importance of this differ-
ence is unclear. Birth weight, in itself, is influenced by a
multitude of factors, including gestational length, mater-
nal nutrition [44], maternal diabetes [45], exposure to
toxins such as maternal smoking [46], maternal age, sex
of the child, socioeconomic status, and birth order [47, 48].
Adjusting for maternal age, gestational length, birth
order, civil status of the mothers and type of birth, in
the multivariate analyses did not affect the point esti-
mates for birth weight. Maternal diabetes was not
linked to the risk of AS in the offspring.
Low birth order was, in a previous study comparing
162 AS cases with their healthy siblings, a risk factor for
developing AS [19]. In contrast to this a much larger
register-based study of AS cases (4517 patients in the
Bath AS register), investigating the position of birth
within the family found no statistically significant effect
of birth order on the risk of developing AS [20]. Due to
their methodology, both of these studies only examined
families with more than one child, in order to assess the
effect of birth order. In our national case–control study,
also including cases without siblings, having older sib-
lings was significantly associated with an increased risk
of later receiving a diagnosis of AS. Studies of IBD have
indicated that having older siblings may be associated
with an increased risk for ulcerative colitis, while having
younger siblings may be associated with a decrease in
risk for Crohn’s disease [49], although results are con-
flicting [50]. In previous studies, it has been shown that
having older siblings constitute a risk for exposure to in-
fections at a very young age [16], and it has been argued
that having younger sibling may constitute a risk for ex-
posure to infections during the later years of childhood
[14]. In our study the available data did not allow us to
assess the effect of having younger siblings. For the re-
lated disease – reactive arthritis – the direct pathogenic
and temporal association with infectious diseases is well
known [11, 12], and for IBD exposure to enteric infec-
tions is known to affect the risk of developing both
Crohn’s disease and ulcerative colitis [50, 51]. Consider-
ing the conflicting results concerning the effect of birth
order on the risk for developing AS in the current and
the two previous studies [19, 20], further studies are
needed, preferably also including information regarding
type, frequency and severity of infections.
Limitations and strengths of this study
Some limitations should be considered. First, misclassifi-
cation of cases may be a problem when using health care
registers for identification. Previous validation studies
performed by our group have, however, demonstrated
high validity for ICD codes for AS in the Swedish
registers [40]. Furthermore, the proportion of men and
women and the frequency of treatment with TNFi were
very similar to that found in previous clinical studies on
AS in Sweden [52], and the frequencies of IBD, psoriasis
and anterior uveitis were also similar to other AS co-
horts [53] (although the gender distribution was more
equal than in some other cohorts [1, 53], which may to
some extent be due to the inclusion of cases with non-
radiographic axial SpA in the AS group, as indicated in
the validation study [40]), supporting the validity of the
case identification. Second, residual or unmeasured con-
founding could be an issue in all observational studies.
We were able to adjust for socioeconomic status to
some extent in our main multivariate analysis, and there
was no statistically significant difference in level of for-
mal education and disposable income in 2008 between
cases and controls. However, other important factors,
such as the family income at birth, mother’s body mass
index (BMI) and the parent’s health status (e.g. ankylos-
ing spondylitis), could not be taken into account in the
analyses. Third, maternal smoking was only available for
32 % of the cases and during a limited time period. In it-
self it did not affect the risk of developing AS in the uni-
variate analyses, but due to the limitations in the
available data it could not be included in the multivariate
analysis. Since smoking is known to be related to both
low birth weight [46] and to predict radiographic pro-
gression in AS [54] the effect of maternal smoking, or
exposure to smoking during childhood, on the risk for
developing AS needs to be studied further. Fourth, due
to the limited time frame of the study, patients with a
long diagnostic delay would not be identified and in-
cluded as cases [40, 55]. Fifth, using birth order as a pos-
sible proxy for childhood infections is inferior to directly
recording actual infectious events, which was not pos-
sible for the cases/controls in this study.
Our study also has several strengths. First, this is the
only study of this research question in AS comparing
cases to population controls. Second, it is based on na-
tional health care registers, capturing the vast majority
of AS cases in Sweden [56], which resulted in relatively
large numbers and few missing data for most variables
and therefore greater generalizability. This also decreases
the risk of selection bias, which may have influenced the
results in the previous studies of the effect of birth order
on the risk for AS [19, 20]. Third, the consistent magni-
tudes and directions of the point estimates in the sensi-
tivity analyses suggest that our results were reasonably
robust.
Conclusions
Our results point to environmental factors as possible
predictors for development of AS. More specifically, we
found that having older siblings increased the risk for a
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later diagnosis of AS, indicating that factors related to
childhood exposure may be of importance in the disease
pathogenesis.
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